marketcap
Facebook
Twitter
Telegram
Report an ErrorQuarterly report 2024-Q2
added 08-08-2024
Revance Therapeutics Cash Flow 2011-2024 | RVNC
Annual Cash Flow Revance Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
-217 M | -194 M | -222 M | -179 M | -106 M | -104 M | -95.3 M | -59.8 M | -55.7 M | -55.1 M | -47.8 M | -38.9 M | - |
Depreciation & Amortization |
11.4 M | 33.7 M | 19.9 M | 10.2 M | 2.91 M | 1.73 M | 1.47 M | 1.44 M | 2 M | 2.05 M | 1.88 M | 1.78 M | - |
Accounts Payables |
13.8 M | 4.55 M | 10.6 M | 12.7 M | 8.01 M | 8.43 M | 6.8 M | 3.75 M | 2.66 M | 3.15 M | - | - | - |
Accounts Receivables |
27.7 M | 11.3 M | 3.35 M | 1.83 M | - | 27 M | 48 K | 75 K | 158 K | 300 K | - | - | - |
Total Inventories |
45.6 M | 18.3 M | 10.2 M | 5.88 M | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Cash Flow Revance Therapeutics
| 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
- | -65.9 M | - | - | - | -69.5 M | - | -163 M | -105 M | -61.3 M | - | -177 M | -124 M | -74.8 M | - | -116 M | -60.5 M | -43.3 M | - | -72.7 M | -40.7 M | -11.4 M | - | -73.1 M | -47.7 M | -11.1 M | - | -66.9 M | -45.5 M | -21.2 M | - | -46.4 M | -32 M | -15.7 M | - | -39.2 M | -25.5 M | -13 M | - | -46 M | -33.3 M | -21.1 M | - | - | - | - | - | - | - | - | - | - | - | - |
Depreciation & Amortization |
546 K | 1.98 M | - | 1.32 M | 717 K | 4.3 M | - | 3.88 M | 3.93 M | 5.38 M | - | 14.4 M | 9.28 M | 4.24 M | - | 5.93 M | 2.15 M | 739 K | - | 2.15 M | 1.42 M | 628 K | - | 1.25 M | 807 K | 390 K | - | 1.1 M | 722 K | 357 K | - | 1.07 M | 699 K | 344 K | - | 1.59 M | 1.08 M | 531 K | - | 600 K | 500 K | 488 K | - | 400 K | 400 K | 453 K | - | - | - | - | - | - | - | - |
Accounts Payables |
4.98 M | 5.28 M | 13.6 M | 4.78 M | 8.34 M | 13 M | 4.55 M | 744 K | 13.3 M | 10 M | 10.6 M | 8.04 M | 8.18 M | 7.08 M | 12.7 M | 12.7 M | 12.7 M | 12.7 M | 8.01 M | 8.01 M | 8.01 M | 8.01 M | 8.43 M | 8.43 M | 8.43 M | 8.43 M | 6.8 M | 6.8 M | 6.8 M | 6.8 M | 3.75 M | 3.75 M | 3.75 M | 3.75 M | 2.66 M | 2.66 M | 2.66 M | 2.66 M | 3.15 M | 3.15 M | 3.15 M | 3.15 M | 5.53 M | 5.53 M | 5.53 M | 5.53 M | - | - | - | - | - | - | - | - |
Accounts Receivables |
36.1 M | 29.9 M | 27.7 M | 25.4 M | 17 M | 15.4 M | 11.3 M | 11.7 M | 5.59 M | 4.47 M | 3.35 M | 1.66 M | 641 K | 5.19 M | 1.83 M | 1.83 M | 1.83 M | 1.83 M | - | - | - | - | 27 M | 27 M | 27 M | 27 M | 48 K | - | - | - | 128 K | - | - | - | 75 K | - | - | - | 300 K | 1.42 M | 188 K | 1.79 M | 225 K | 225 K | 225 K | 225 K | - | - | - | - | - | - | - | - |
Total Inventories |
68.3 M | 50.3 M | 45.6 M | 46.2 M | 34.4 M | 27.8 M | 18.3 M | 17.2 M | 13.6 M | 10.7 M | 10.2 M | 10.2 M | 5.06 M | 5.63 M | 5.88 M | 5.88 M | 5.88 M | 5.88 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency